MA44479B1 - Arn transrepliquant - Google Patents
Arn transrepliquantInfo
- Publication number
- MA44479B1 MA44479B1 MA44479A MA44479A MA44479B1 MA 44479 B1 MA44479 B1 MA 44479B1 MA 44479 A MA44479 A MA 44479A MA 44479 A MA44479 A MA 44479A MA 44479 B1 MA44479 B1 MA 44479B1
- Authority
- MA
- Morocco
- Prior art keywords
- present
- rna
- protein
- alphavirus
- replicase
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 241000710929 Alphavirus Species 0.000 abstract 4
- 108010026228 mRNA guanylyltransferase Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne de manière générale des systèmes et des procédés appropriés pour une production protéinique de niveau élevé. Tandis qu'un ou plusieurs éléments de la présente invention sont dérivés d'un alphavirus, la présente invention ne nécessite pas de propagation de particules virales. En particulier, un système comprenant deux molécules d'arn séparées est prévu, comprenant chacune une séquence nucléotidique dérivée d'un alphavirus : une molécule d'arn comprend une construction d'arn pour exprimer une réplicase d'alphavirus et une molécule d'arn comprend un réplicon d'arn qui peut être répliqué par la réplicase en trans. La construction d'arn pour exprimer une réplicase d'alphavirus comprend une coiffe en position 5'. Il a été découvert de manière surprenante que la coiffe en position 5' est appropriée pour entraîner efficacement l'expression d'un transgène à partir du réplicon en trans. Le système de la présente invention permet l'expression d'une protéine d'intérêt dans une cellule ou un organisme, mais n'est pas associé à une formation non souhaitée de particules virales. Par conséquent, la présente invention est appropriée pour une production efficace et sûre d'une protéine d'intérêt, par exemple une protéine thérapeutique ou une protéine antigénique, telle qu'un vaccin, dans un organisme cible. L'invention concerne des procédés respectifs de production de protéines in vitro et in vivo ainsi que des utilisations médicales. La présente invention concerne également un adn codant pour les molécules d'arn de l'invention et des cellules comprenant les molécules d'arn de l'invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/056160 WO2017162265A1 (fr) | 2016-03-21 | 2016-03-21 | Arn à réplication trans |
PCT/EP2017/055813 WO2017162461A1 (fr) | 2016-03-21 | 2017-03-13 | Arn à réplication trans |
Publications (2)
Publication Number | Publication Date |
---|---|
MA44479A MA44479A (fr) | 2021-04-21 |
MA44479B1 true MA44479B1 (fr) | 2021-11-30 |
Family
ID=55586324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44479A MA44479B1 (fr) | 2016-03-21 | 2017-03-13 | Arn transrepliquant |
Country Status (26)
Country | Link |
---|---|
US (1) | US20200299724A1 (fr) |
EP (2) | EP3433368B1 (fr) |
JP (2) | JP7105193B2 (fr) |
KR (1) | KR102441725B1 (fr) |
CN (2) | CN109328233B (fr) |
AU (1) | AU2017236240B2 (fr) |
BR (1) | BR112018068391A2 (fr) |
CA (1) | CA3017285A1 (fr) |
CY (1) | CY1124689T1 (fr) |
DK (1) | DK3433368T3 (fr) |
ES (1) | ES2896927T3 (fr) |
HR (1) | HRP20211715T1 (fr) |
HU (1) | HUE058889T2 (fr) |
IL (1) | IL261327B1 (fr) |
LT (1) | LT3433368T (fr) |
MA (1) | MA44479B1 (fr) |
MD (1) | MD3433368T2 (fr) |
MX (1) | MX2018011384A (fr) |
PL (1) | PL3433368T3 (fr) |
PT (1) | PT3433368T (fr) |
RS (1) | RS62543B1 (fr) |
RU (1) | RU2752580C2 (fr) |
SG (1) | SG11201807378SA (fr) |
SI (1) | SI3433368T1 (fr) |
WO (2) | WO2017162265A1 (fr) |
ZA (2) | ZA201805520B (fr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP4218805A1 (fr) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Vaccins contre les maladies infectieuses |
WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
WO2019053056A1 (fr) * | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | Réplicon d'arn permettant d'exprimer un récepteur de lymphocyte t ou un récepteur de lymphocyte t artificiel |
EP3681993A1 (fr) * | 2017-09-13 | 2020-07-22 | BioNTech RNA Pharmaceuticals GmbH | Réplicon d'arn pour la reprogrammation de cellules somatiques |
WO2019055807A1 (fr) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Vaccins à arn contre le virus zika |
US10736957B2 (en) * | 2017-12-19 | 2020-08-11 | President And Fellows Of Harvard College | Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences |
WO2021138447A1 (fr) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Administration transitoire basée sur la température d'acides nucléiques et de protéines à des cellules et des tissus |
EP4103228A1 (fr) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Vaccin à base d'acide nucléique contre le coronavirus sars-cov-2 |
KR102462990B1 (ko) * | 2020-03-17 | 2022-11-07 | 에이비온 주식회사 | 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물 |
EP4171629A1 (fr) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
US11771652B2 (en) | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
GB202020063D0 (en) | 2020-12-17 | 2021-02-03 | Imperial College Innovations Ltd | RNA construct |
GB202020061D0 (en) | 2020-12-17 | 2021-02-03 | Imp College Innovations Ltd | RNA construct |
GB202020064D0 (en) | 2020-12-17 | 2021-02-03 | Imperial College Innovations Ltd | RNA construct |
CN112852841A (zh) | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
WO2022200574A1 (fr) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Compositions immunogènes |
WO2022228827A1 (fr) | 2021-04-26 | 2022-11-03 | Institut Pasteur | Anticorps monoclonaux neutralisants humains contre le sras-cov-2 et leurs utilisations |
WO2022234268A1 (fr) * | 2021-05-04 | 2022-11-10 | Mogrify Limited | Conversion cellulaire |
WO2022248353A1 (fr) | 2021-05-24 | 2022-12-01 | Glaxosmithkline Biologicals Sa | Adjuvants |
US20220396798A1 (en) * | 2021-06-12 | 2022-12-15 | Shi-Lung Lin | Novel mrna composition and production method for use in anti-viral and anti-cancer vaccines |
IL309408A (en) | 2021-06-18 | 2024-02-01 | Sanofi Sa | Multivalent flu vaccines |
WO2023020994A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Nouveaux procédés |
WO2023020993A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Nouveaux procédés |
WO2023020992A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Nouveaux procédés |
WO2023021421A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Vaccins à base d'arn lyophilisés à faible dose et leurs procédés de préparation et d'utilisation |
WO2023021427A1 (fr) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Lyophilisation de nanoparticules lipidiques (lnp) encapsulant de l'arn et leurs formulations |
AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
WO2023056980A1 (fr) * | 2021-10-09 | 2023-04-13 | 吴可行 | Conception de molécules d'arn auto-réplicatives et leur application |
AU2022372325A1 (en) | 2021-10-18 | 2024-05-02 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
EP4285933A1 (fr) | 2022-05-30 | 2023-12-06 | BioNTech SE | Complexes oligosaccharides et utilisations |
EP4286004A1 (fr) | 2022-05-30 | 2023-12-06 | BioNTech SE | Composés et complexes d'oligosaccharide de disulfure |
EP4169534A1 (fr) | 2021-10-22 | 2023-04-26 | BioNTech SE | Complexes oligosaccharides et utilisations |
EP4169580A1 (fr) | 2021-10-22 | 2023-04-26 | BioNTech SE | Composés et complexes d'oligosaccharide |
EP4285932A1 (fr) | 2022-05-30 | 2023-12-06 | BioNTech SE | Complexes oligosaccharides et utilisations |
EP4186528A1 (fr) | 2021-11-30 | 2023-05-31 | BioNTech SE | Complexes oligosaccharides et utilisations |
EP4286003A1 (fr) | 2022-05-30 | 2023-12-06 | BioNTech SE | Composés et complexes d'oligosaccharide |
WO2023067126A1 (fr) | 2021-10-22 | 2023-04-27 | BioNTech SE | Composés et complexes oligosaccharidiques |
EP4169579A1 (fr) | 2021-10-22 | 2023-04-26 | BioNTech SE | Composés et complexes d'oligosaccharide de disulfure |
WO2023067124A1 (fr) | 2021-10-22 | 2023-04-27 | BioNTech SE | Composés et complexes d'oligosaccharides de disulfure |
EP4286394A1 (fr) | 2022-05-30 | 2023-12-06 | BioNTech SE | Composés et complexes d'oligosaccharide |
WO2023067123A1 (fr) | 2021-10-22 | 2023-04-27 | BioNTech SE | Complexes d'oligosaccharides et leurs utilisations |
EP4169578A1 (fr) | 2021-10-22 | 2023-04-26 | BioNTech SE | Composés et complexes d'oligosaccharide |
WO2023067125A1 (fr) | 2021-10-22 | 2023-04-27 | BioNTech SE | Complexes oligosaccharidiques et leurs utilisations |
AU2022369405A1 (en) | 2021-10-22 | 2024-05-09 | BioNTech SE | Oligosaccharide compounds and complexes |
AR127585A1 (es) | 2021-11-05 | 2024-02-07 | Sanofi Sa | Vacuna de arn de virus sincicial respiratorio |
WO2023083434A1 (fr) | 2021-11-09 | 2023-05-19 | BioNTech SE | Arn codant pour la peptidoglycane hydrolase et son utilisation pour le traitement d'une infection bactérienne |
WO2023111262A1 (fr) | 2021-12-17 | 2023-06-22 | Sanofi | Vaccin à base d'arn contre la maladie de lyme |
WO2023214082A2 (fr) | 2022-05-06 | 2023-11-09 | Sanofi | Séquences de signaux pour vaccins à base d'acides nucléiques |
WO2023232747A1 (fr) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes pour l'administration d'acides nucléiques |
WO2024044108A1 (fr) | 2022-08-22 | 2024-02-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccins contre les coronavirus |
WO2024068674A1 (fr) | 2022-09-26 | 2024-04-04 | BioNTech SE | Complexes d'acide nucléique et leurs utilisations |
WO2024086549A1 (fr) * | 2022-10-17 | 2024-04-25 | The University Of North Carolina At Chapel Hill | Alphavirus chimériques pour évolution dirigée |
WO2024084462A1 (fr) | 2022-10-21 | 2024-04-25 | BioNTech SE | Complexes d'acide nucléique et leurs utilisations |
WO2024083345A1 (fr) | 2022-10-21 | 2024-04-25 | BioNTech SE | Procédés et utilisations associés à des compositions liquides |
WO2024094881A1 (fr) | 2022-11-04 | 2024-05-10 | Sanofi | Vaccination à arn contre le virus respiratoire syncytial |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2353282C (en) * | 1998-03-20 | 2013-02-27 | State Queensland Primary Ind | Control of gene expression |
IL145221A0 (en) | 1999-03-09 | 2002-12-01 | Large Scale Biology Corp Unive | Multiple component rna vector system for expression of foreign sequences |
WO2002018585A2 (fr) * | 2000-08-29 | 2002-03-07 | Wyeth Holdings Corporation | Encapsidation de particules de replicon de virus d'arn a chaine positive |
EP2305299B1 (fr) * | 2001-05-31 | 2017-03-01 | GlaxoSmithKline Biologicals SA | Particules de replicon d'alphavirus chimerique |
US20030232324A1 (en) * | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
ES2330202T5 (es) * | 2001-09-06 | 2014-01-20 | Alphavax, Inc. | Sistemas vectores basados en replicones de alfavirus |
WO2003085114A1 (fr) | 2002-04-01 | 2003-10-16 | Walter Reed Army Institute Of Research | Procede pour concevoir des sequences d'acides nucleiques de synthese pour l'expression optimale de proteines dans une cellule hote |
US7442381B2 (en) * | 2003-03-20 | 2008-10-28 | Alphavax, Inc. | Alphavirus replicons and helper constructs |
EP2811027A1 (fr) * | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Vecteurs alphavirus pour vaccins contre le VRS et le PIV |
WO2008119827A1 (fr) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Produits de synthèse transréplicases |
PL2167523T3 (pl) | 2007-06-19 | 2014-12-31 | Univ Louisiana State | Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA |
AU2008266807B2 (en) * | 2007-06-21 | 2012-08-16 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
EA022990B1 (ru) | 2007-08-20 | 2016-04-29 | Глаксо Груп Лимитед | Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок |
PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
EP2281579A1 (fr) | 2009-08-05 | 2011-02-09 | BioNTech AG | Composition de vaccin comportant un ADN modifié 5'-Cap |
WO2012006378A1 (fr) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn |
US9192661B2 (en) * | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
BR112013000392B8 (pt) * | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso |
CA2804591C (fr) | 2010-07-06 | 2019-01-22 | Novartis Ag | Emulsions cationiques huile-dans-eau |
LT4066855T (lt) | 2010-08-31 | 2023-03-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr tiekimui |
BR112013004865A2 (pt) | 2010-08-31 | 2016-06-07 | Novartis Ag | lípidos adequados para entrega lipossomal de codificadores de proteínas rna |
PT4008357T (pt) | 2010-08-31 | 2023-01-11 | Glaxosmithkline Biologicals Sa | Lipossomas pequenos para entrega de arn que codifica um imunogénio |
ES2716243T3 (es) * | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
RU2649133C2 (ru) | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
EP3424495A1 (fr) | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Émulsions aqueuses contenant des acides nucléiques |
ES2656050T3 (es) * | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Composiciones de combinación inmunogénica y usos de las mismas |
EP2729126B1 (fr) | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes ayant un rapport n:p utile pour délivrance de molécules d'arn |
SG11201400250UA (en) | 2011-08-31 | 2014-03-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
JP6305925B2 (ja) * | 2011-10-11 | 2018-04-18 | ノバルティス アーゲー | 組換え自己複製ポリシストロニックrna分子 |
BR122019027913B1 (pt) * | 2011-11-11 | 2021-11-30 | Variation Biotechnologies, Inc | Partícula vírus-like, composição farmacêutica compreendendo a referida partícula e método para produção da mesma |
WO2013143555A1 (fr) | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
SG10201607962RA (en) | 2012-03-27 | 2016-11-29 | Curevac Ag | Artificial nucleic acid molecules |
MX2019002345A (es) | 2012-03-27 | 2022-08-24 | Curevac Ag | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. |
WO2014071963A1 (fr) | 2012-11-09 | 2014-05-15 | Biontech Ag | Procédé pour l'expression d'arn cellulaire |
WO2014170493A2 (fr) * | 2013-04-19 | 2014-10-23 | Novartis Ag | Vecteur d'alphavirus |
WO2016005004A1 (fr) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilisation de séquences d'adn codant pour une séquence poly (a) |
KR20200049856A (ko) * | 2017-09-13 | 2020-05-08 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | 세포에서 rna 발현을 향상시키는 방법 |
-
2016
- 2016-03-21 WO PCT/EP2016/056160 patent/WO2017162265A1/fr active Application Filing
-
2017
- 2017-03-13 KR KR1020187027526A patent/KR102441725B1/ko active IP Right Grant
- 2017-03-13 EP EP17710268.8A patent/EP3433368B1/fr active Active
- 2017-03-13 US US16/086,127 patent/US20200299724A1/en active Pending
- 2017-03-13 MX MX2018011384A patent/MX2018011384A/es unknown
- 2017-03-13 WO PCT/EP2017/055813 patent/WO2017162461A1/fr active Application Filing
- 2017-03-13 ES ES17710268T patent/ES2896927T3/es active Active
- 2017-03-13 JP JP2018549306A patent/JP7105193B2/ja active Active
- 2017-03-13 SI SI201730973T patent/SI3433368T1/sl unknown
- 2017-03-13 EP EP21200788.4A patent/EP3964584A1/fr active Pending
- 2017-03-13 HR HRP20211715TT patent/HRP20211715T1/hr unknown
- 2017-03-13 MA MA44479A patent/MA44479B1/fr unknown
- 2017-03-13 HU HUE17710268A patent/HUE058889T2/hu unknown
- 2017-03-13 PL PL17710268T patent/PL3433368T3/pl unknown
- 2017-03-13 LT LTEPPCT/EP2017/055813T patent/LT3433368T/lt unknown
- 2017-03-13 SG SG11201807378SA patent/SG11201807378SA/en unknown
- 2017-03-13 CA CA3017285A patent/CA3017285A1/fr active Pending
- 2017-03-13 CN CN201780018575.8A patent/CN109328233B/zh active Active
- 2017-03-13 BR BR112018068391A patent/BR112018068391A2/pt not_active Application Discontinuation
- 2017-03-13 DK DK17710268.8T patent/DK3433368T3/da active
- 2017-03-13 RS RS20211377A patent/RS62543B1/sr unknown
- 2017-03-13 MD MDE20190126T patent/MD3433368T2/ro unknown
- 2017-03-13 IL IL261327A patent/IL261327B1/en unknown
- 2017-03-13 PT PT177102688T patent/PT3433368T/pt unknown
- 2017-03-13 AU AU2017236240A patent/AU2017236240B2/en active Active
- 2017-03-13 RU RU2018131783A patent/RU2752580C2/ru active
- 2017-03-13 CN CN202211115420.5A patent/CN115386596A/zh active Pending
-
2018
- 2018-08-17 ZA ZA201805520A patent/ZA201805520B/en unknown
-
2019
- 2019-08-15 ZA ZA2019/05396A patent/ZA201905396B/en unknown
-
2021
- 2021-09-30 JP JP2021160491A patent/JP7421256B2/ja active Active
- 2021-11-03 CY CY20211100949T patent/CY1124689T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44479B1 (fr) | Arn transrepliquant | |
Fujita et al. | Clinical application of mesenchymal stem cell-derived extracellular vesicle-based therapeutics for inflammatory lung diseases | |
Van der Jeught et al. | Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety | |
KR20190110612A (ko) | 활성화 종양유전자 돌연변이 펩티드를 인코드하는 면역조절 치료 mrna 조성물 | |
MY193112A (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
WO2014172470A3 (fr) | Procedes de mutation, de modification ou de modulation d'acide nucleique dans une cellule ou chez un mammifere non-humain | |
MA40713A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
MA42072A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers | |
MA40813A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs | |
MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
MA43075A1 (fr) | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers | |
MA40794A1 (fr) | Nouveaux peptides et combinaisons de peptides et d'échafaudages destinés à être utilisés en immunothérapie contre le carcinome hépatocellulaire (chc) et d'autres cancers | |
MA43466A1 (fr) | Traitements du cancer de l'utérus | |
CY1123343T1 (el) | Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων | |
EA201790953A1 (ru) | Изменение экспрессии гена в cart-клетках и их применения | |
Bahmani et al. | Different sourced extracellular vesicles and their potential applications in clinical treatments | |
Bukari et al. | Non-invasive delivery of therapeutics into the brain: the potential of aptamers for targeted delivery | |
Araldi et al. | Stem cell-derived exosomes as therapeutic approach for neurodegenerative disorders: from biology to biotechnology | |
EA201492014A1 (ru) | Получение ротавирус-подобных частиц в растениях | |
JP2022058995A (ja) | 操作されたTreg細胞 | |
CN114727947A (zh) | 细胞外囊泡组合物 | |
MA46140A (fr) | Facteur de transcription nterf241 et ses procédés d'utilisation | |
JP2018534932A5 (fr) | ||
De Bousser et al. | T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy | |
MA43482A1 (fr) | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers |